Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ADMA Biologics revenue
ADMA Biologics's revenue is $426.5 million.
What is ADMA Biologics's revenue?
- ADMA Biologics annual revenue for 2024 was 426.5M, 65.15% growth from 2023.
- ADMA Biologics's revenue growth from 2011 to 2024 is 55,935.54%.
- ADMA Biologics has 314 employees, and the revenue per employee ratio is $1,358,133.
- ADMA Biologics's peak quarterly revenue was $119.8M in 2024(q3).
- ADMA Biologics peak revenue was $426.5M in 2024.
- ADMA Biologics annual revenue for 2023 was 258.2M, 67.59% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
ADMA Biologics historical revenue
ADMA Biologics's peak revenue was $426.5M in 2024. The peak quarterly revenue was $119.8M in 2024(q3).
ADMA Biologics's revenue increased from $761.0k in 2011 to $426.5M currently. That's a 55,935.54% change in annual revenue.
ADMA Biologics annual revenue
ADMA Biologics annual revenue over time
| Fiscal year / year | ADMA Biologics revenue |
|---|---|
| 2011 | $761,042 |
| 2012 | $1.1M |
| 2013 | $3.1M |
| 2014 | $5.9M |
| 2015 | $7.2M |
| 2016 | $10.7M |
| 2017 | $22.8M |
| 2018 | $17.0M |
| 2019 | $29.3M |
| 2020 | $42.2M |
| 2021 | $80.9M |
| 2022 | $154.1M |
| 2023 | $258.2M |
| 2024 | $426.5M |
Rate ADMA Biologics' financial transparency
ADMA Biologics annual growth
ADMA Biologics saw the greatest revenue growth in 2013, when revenue increased by 174.35%.
ADMA Biologics had the lowest revenue growth in 2018, when revenue changed by -25.37%.
ADMA Biologics annual growth rate over time
| Year | ADMA Biologics growth |
|---|---|
| 2012 | 47%↑ |
| 2013 | 174%↑ |
| 2014 | 93%↑ |
| 2015 | 21%↑ |
| 2016 | 49%↑ |
| 2017 | 113%↑ |
| 2018 | -25%↓ |
| 2019 | 73%↑ |
| 2020 | 44%↑ |
| 2021 | 92%↑ |
| 2022 | 90%↑ |
| 2023 | 68%↑ |
| 2024 | 65%↑ |
ADMA Biologics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
ADMA Biologics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | $4,400 | $230,096 | $360,338 | $523,284 |
| 2013 | $792,935 | $743,270 | $1.1M | $424,031 |
| 2014 | $1.6M | $1.5M | $1.4M | $1.5M |
| 2015 | $1.5M | $1.3M | $1.9M | $2.5M |
| 2016 | $2.1M | $2.3M | $2.9M | $3.3M |
| 2017 | $2.6M | $3.4M | $4.7M | $12.0M |
| 2018 | $4.0M | $4.7M | $4.2M | $4.1M |
| 2019 | $3.5M | $6.6M | $7.2M | $12.0M |
| 2020 | $10.2M | $7.8M | $10.3M | $14.0M |
| 2021 | $16.0M | $17.8M | $20.7M | $26.4M |
| 2022 | $29.1M | $33.9M | $41.1M | $50.0M |
| 2023 | $56.9M | $60.1M | $67.3M | $73.9M |
| 2024 | $81.9M | $107.2M | $119.8M | $117.5M |
ADMA Biologics jobs nearby
Do you work at ADMA Biologics?
Is ADMA Biologics transparent about its revenue structure?
ADMA Biologics financial information
| CEO | Adam S. Grossman |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 314 |
| Date Founded | 2004 |
| Headquarters | Ramsey, New Jersey |
| Number of Locations | 5 |
| Revenue | $426.5M |
| Net Income | -$65,903,950 |
| Gross Proft | $219.6M (2024) |
| EBITDA | $137.9M (2024) |
| PE Ratio | 0.40 |
| Tax Rate | -0.6% |
| Market Capitalization | $78.7M |
| Total Assets | $348,461,881 |
| Ticker | ADMA |
ADMA Biologics jobs you might like
ADMA Biologics financing
ADMA Biologics received early financing of $17.5M on 2012-02-13.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $17.5M | 02/2012 |
| Debt Financing | $6M | 01/2013 |
| Post Ipo Debt | $15M | 02/2014 |
| Post Ipo Debt | $5M | 12/2014 |
| Post Ipo Equity | $10.3M | 03/2015 |
| Post Ipo Debt | $21M | 06/2015 |
| Post Ipo Debt | $4M | 05/2016 |
| Post Ipo Debt | $30M | 10/2017 |
| Post Ipo Equity | $42M | 11/2017 |
| Post Ipo Equity | $40M | 06/2018 |
| Post Ipo Debt | $72.5M | 02/2019 |
| Post Ipo Equity | $51.8M | 05/2019 |
| Post Ipo Equity | $82.3M | 02/2020 |
| Post Ipo Debt | $150M | 03/2022 |
ADMA Biologics investors
| Investors | Security type |
|---|---|
| Burrill & Company | Series Unknown |
| Biomark Capital | Series Unknown |
| Aisling Capital | Series Unknown |
| HERCULES CAPITAL INC | Debt Financing |
| HERCULES CAPITAL INC | Post Ipo Debt |
| HERCULES CAPITAL INC | Post Ipo Debt |
| Oxford Finance LLC | Post Ipo Debt |
| Oxford Finance LLC | Post Ipo Debt |
| Marathon Asset Management | Post Ipo Debt |
| Perceptive Advisors | Post Ipo Debt |
| HAYFIN CAPITAL MANAGEMENT LLP | Post Ipo Debt |
ADMA Biologics competitors
ADMA Biologics's top competitor, Solstas Lab Partners Group, LLC, earned an annual revenue of $270.0M.
ADMA Biologics's smallest competitor is Diagnostic Laboratory Services with revenue of $390.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Central Pennsylvania Blood Bnk | $42,035 | $50.0M | 91 | - |
| Coastal Bend Blood Center | $40,883 | $50.0M | 76 | - |
| Indiana Blood Center | $38,457 | $51.4M | 225 | - |
| Biomat Usa, Inc. | $37,487 | $250.0M | 750 | 87 |
| Oklahoma Blood Institute | $33,101 | $100.0M | 680 | 31 |
| Community Blood Center | $40,035 | $50.0M | 64 | 13 |
| American Health Associates, Inc. | $40,988 | $6.5M | 50 | 99 |
| Schryver Medical | $38,387 | $130.0M | 200 | - |
| East Side Clinical Laboratory | $33,611 | $23.0M | 175 | 7 |
| ProLab | $35,716 | $13.0M | 200 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of ADMA Biologics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ADMA Biologics. The employee data is based on information from people who have self-reported their past or current employments at ADMA Biologics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ADMA Biologics. The data presented on this page does not represent the view of ADMA Biologics and its employees or that of Zippia.
ADMA Biologics may also be known as or be related to ADMA BIOLOGICS INC., ADMA BIOLOGICS, INC., ADMA Biologics, ADMA Biologics Inc, ADMA Biologics, Inc., ADMA PLASMA BIOLOGICS INC. and Adma Biologics, Inc.